Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ESMO

- PMLiVE

Researchers uncover role of inherited genetic variants in rare blood cancer

There are around 4,000 cases of myeloproliferative neoplasms in the UK each year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Novartis shares positive phase 3 results for Lutathera in neuroendocrine tumours

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Impetus Digital

- PMLiVE

Merck granted FDA approval for Keytruda combination in cervical cancer

The decision marks the third FDA-approved indication for Keytruda in cervical cancer

- PMLiVE

UK national study supports whole genome sequencing in standard cancer care

The trial combined data from the UK’s 100,000 Genomes Project and NHS records

- PMLiVE

Study identifies hundreds of priority targets for cancer drug discovery

Researchers identified 370 priority drug candidates across 27 types of cancer

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links